In last trading session, Spyre Therapeutics Inc (NASDAQ:SYRE) saw 0.43 million shares changing hands with its beta currently measuring 2.91. Company’s recent per share price level of $39.58 trading at $1.89 or 5.00% at ring of the bell on the day assigns it a market valuation of $2.02B. That closing price of SYRE’s stock is at a discount of -21.2% from its 52-week high price of $47.97 and is indicating a premium of 78.7% from its 52-week low price of $8.43. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.4 million shares which gives us an average trading volume of 477.26K if we extend that period to 3-months.
For Spyre Therapeutics Inc (SYRE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.11. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.76 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Spyre Therapeutics Inc (NASDAQ:SYRE) trade information
Upright in the green during last session for gaining 5.00%, in the last five days SYRE remained trading in the green while hitting it’s week-highest on Friday, 11/08/24 when the stock touched $39.58 price level, adding 0.13% to its value on the day. Spyre Therapeutics Inc’s shares saw a change of 83.90% in year-to-date performance and have moved 16.47% in past 5-day. Spyre Therapeutics Inc (NASDAQ:SYRE) showed a performance of 45.39% in past 30-days. Number of shares sold short was 8.41 million shares which calculate 13.78 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 40 to the stock, which implies a rise of 1.05% to its current value. Analysts have been projecting 40 as a low price target for the stock while placing it at a high target of 50. It follows that stock’s current price would drop -1.06% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1.06% for stock’s current value.
Spyre Therapeutics Inc (SYRE) estimates and forecasts
Statistics highlight that Spyre Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 7.16% of value to its shares in past 6 months, showing an annual growth rate of 86.06% while that of industry is 16.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 295.00% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 3.5M for the same.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 1.60% during past 5 years.
Spyre Therapeutics Inc (NASDAQ:SYRE)’s Major holders
FAIRMOUNT FUNDS MANAGEMENT LLC is the top institutional holder at SYRE for having 4.02 million shares of worth $94.47 million. And as of 2024-06-30, it was holding 8.8668 of the company’s outstanding shares.
The second largest institutional holder is RTW INVESTMENTS, LP, which was holding about 3.26 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.1903 of outstanding shares, having a total worth of $76.6 million.
